121 related articles for article (PubMed ID: 28885659)
1. The role of serum neuron-specific enolase in patients with prostate cancer: a systematic review of the recent literature.
Muoio B; Pascale M; Roggero E
Int J Biol Markers; 2018 Jan; 33(1):10-21. PubMed ID: 28885659
[TBL] [Abstract][Full Text] [Related]
2. Chromogranin A and neurone-specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer.
Fan L; Wang Y; Chi C; Pan J; Xun S; Xin Z; Hu J; Zhou L; Dong B; Xue W
BJU Int; 2017 Aug; 120(2):226-232. PubMed ID: 28107595
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer.
Szarvas T; Csizmarik A; Fazekas T; Hüttl A; Nyirády P; Hadaschik B; Grünwald V; Püllen L; Jurányi Z; Kocsis Z; Shariat SF; Sevcenco S; Maj-Hes A; Kramer G
BJU Int; 2021 Jan; 127(1):44-55. PubMed ID: 32314509
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment serum level of neuron specific enolase (NSE) as a prognostic factor in metastatic prostate cancer patients treated with endocrine therapy.
Kamiya N; Akakura K; Suzuki H; Isshiki S; Komiya A; Ueda T; Ito H
Eur Urol; 2003 Sep; 44(3):309-14; discussion 314. PubMed ID: 12932928
[TBL] [Abstract][Full Text] [Related]
5. Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy.
Heck MM; Thaler MA; Schmid SC; Seitz AK; Tauber R; Kübler H; Maurer T; Thalgott M; Hatzichristodoulou G; Höppner M; Nawroth R; Luppa PB; Gschwend JE; Retz M
BJU Int; 2017 Jan; 119(1):30-37. PubMed ID: 27037533
[TBL] [Abstract][Full Text] [Related]
6. Serum Neuroendocrine Markers Predict Therapy Outcome of Patients with Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis.
Liu Y; Zhao S; Wang J; Zhu Z; Luo L; Li E; Tang F; Zhao Z
Urol Int; 2019; 102(4):373-384. PubMed ID: 30517936
[TBL] [Abstract][Full Text] [Related]
7. Prospective Evaluation of Neuromediator Dynamics in Castration-Resistant Prostate Cancer Patients During Docetaxel.
VON Hardenberg J; Schwartz M; Werner T; Fuxius S; Müller M; Frangenheim T; Bolenz C; Weiss C; Heinrich E
Anticancer Res; 2017 Sep; 37(9):5117-5124. PubMed ID: 28870943
[TBL] [Abstract][Full Text] [Related]
8. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer.
Sainio M; Visakorpi T; Tolonen T; Ilvesaro J; Bova GS
Pathol Res Pract; 2018 Jun; 214(6):848-856. PubMed ID: 29728311
[TBL] [Abstract][Full Text] [Related]
9. The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonic antigen and neuron-specific enolase in lung cancer patients.
Zhang L; Liu D; Li L; Pu D; Zhou P; Jing Y; Yu H; Wang Y; Zhu Y; He Y; Li Y; Zhao S; Qiu Z; Li W
BMC Cancer; 2017 Feb; 17(1):96. PubMed ID: 28152979
[TBL] [Abstract][Full Text] [Related]
10. Neuron-specific enolase as a prognostic factor in metastatic malignant melanoma.
Wibe E; Hannisdal E; Paus E; Aamdal S
Eur J Cancer; 1992; 28A(10):1692-5. PubMed ID: 1389487
[TBL] [Abstract][Full Text] [Related]
11. Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naïve castration-resistant prostate cancer.
von Hardenberg J; Schwartz M; Werner T; Fuxius S; Müller M; Bolenz C; Weiß C; Heinrich E
Prostate; 2016 May; 76(7):613-9. PubMed ID: 26779767
[TBL] [Abstract][Full Text] [Related]
12. Investigation on serum neurone-specific enolase in prostate cancer diagnosis and monitoring: comparative study of a multiple tumor marker assay.
Tarle M; Radoś N
Prostate; 1991; 19(1):23-33. PubMed ID: 1715080
[TBL] [Abstract][Full Text] [Related]
13. Neuron specific enolase and prognosis of non-small cell lung cancer: a systematic review and meta-analysis.
Yan HJ; Tan Y; Gu W
J BUON; 2014; 19(1):153-6. PubMed ID: 24659657
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of neuron-specific enolase for small cell lung cancer: a systematic review and meta-analysis.
Tian Z; Liang C; Zhang Z; Wen H; Feng H; Ma Q; Liu D; Qiang G
World J Surg Oncol; 2020 May; 18(1):116. PubMed ID: 32473655
[TBL] [Abstract][Full Text] [Related]
15. [Biomarkers in metastatic castration-resistant prostate cancer].
Miller K
Aktuelle Urol; 2015 Jan; 46(1):66-70. PubMed ID: 25658233
[TBL] [Abstract][Full Text] [Related]
16. [The changes in serum neuron-specific enolase in patients with small cell lung cancer].
Taitou H; Sakurai M; Tamura T; Sasaki Y; Eguchi K; Shinkai T; Ookura H; Saijo N
Gan To Kagaku Ryoho; 1987 Nov; 14(11):3046-9. PubMed ID: 2823722
[TBL] [Abstract][Full Text] [Related]
17. Pro-gastrin-releasing peptide and neuron-specific enolase: useful predictors of response to chemotherapy and survival in patients with small cell lung cancer.
Huang Z; Xu D; Zhang F; Ying Y; Song L
Clin Transl Oncol; 2016 Oct; 18(10):1019-25. PubMed ID: 26886220
[TBL] [Abstract][Full Text] [Related]
18. Neuron-specific enolase in testicular cancer--clinical experiences with serum neuron-specific enolase in patients with testicular cancer at diagnosis and during follow-up.
Tandstad T; Klepp O
Acta Oncol; 2003; 42(3):202-6. PubMed ID: 12852696
[TBL] [Abstract][Full Text] [Related]
19. Neuroendocrine serum tumour markers in hormone-resistant prostate cancer.
Hvamstad T; Jordal A; Hekmat N; Paus E; Fosså SD
Eur Urol; 2003 Aug; 44(2):215-21. PubMed ID: 12875941
[TBL] [Abstract][Full Text] [Related]
20. Neuron-specific enolase--a serum tumour marker in seminoma?
Fosså SD; Klepp O; Paus E
Br J Cancer; 1992 Feb; 65(2):297-9. PubMed ID: 1739633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
